141 related articles for article (PubMed ID: 18452095)
21. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422
[TBL] [Abstract][Full Text] [Related]
22. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2013 Aug; 88(8):703-11. PubMed ID: 23784973
[TBL] [Abstract][Full Text] [Related]
23. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.
Schop RF; Van Wier SA; Xu R; Ghobrial I; Ahmann GJ; Greipp PR; Kyle RA; Dispenzieri A; Lacy MQ; Rajkumar SV; Gertz MA; Fonseca R
Cancer Genet Cytogenet; 2006 Sep; 169(2):150-3. PubMed ID: 16938573
[TBL] [Abstract][Full Text] [Related]
24. A phase II trial on alpha-interferon (alpha IFN) effect in patients with monoclonal IgM gammopathy.
Rotoli B; De Renzo A; Frigeri F; Buffardi S; Marcenò R; Cavallaro AM; Ruggeri P; Liso V; Musto P; Andriani A
Leuk Lymphoma; 1994 May; 13(5-6):463-9. PubMed ID: 8069191
[TBL] [Abstract][Full Text] [Related]
25. IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.
Boyle E; Manier S; Lejeune J; Fouquet G; Guidez S; Bonnet S; Debarri H; Demarquette H; Dulery R; Gay J; Hennache B; Onraed B; Faucompré JL; Schraen S; Facon T; Avet-Loiseau H; Chevret S; Leblond V; Harding S; Leleu X
Clin Cancer Res; 2016 Oct; 22(20):5152-5158. PubMed ID: 27169996
[TBL] [Abstract][Full Text] [Related]
26. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
27. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.
Bustoros M; Sklavenitis-Pistofidis R; Kapoor P; Liu CJ; Kastritis E; Zanwar S; Fell G; Abeykoon JP; Hornburg K; Neuse CJ; Marinac CR; Liu D; Soiffer J; Gavriatopoulou M; Boehner C; Cappuccio JM; Dumke H; Reyes K; Soiffer RJ; Kyle RA; Treon SP; Castillo JJ; Dimopoulos MA; Ansell SM; Trippa L; Ghobrial IM
J Clin Oncol; 2019 Jun; 37(16):1403-1411. PubMed ID: 30990729
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival.
Pratt G; Thomas P; Marden N; Alexander D; Davis Z; Hussey D; Parry H; Harding S; Catovsky D; Begley J; Oscier D
Leuk Lymphoma; 2016 Oct; 57(10):2342-50. PubMed ID: 26732125
[TBL] [Abstract][Full Text] [Related]
29. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
30. Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Papasotiriou I; Fotiou D; Migkou M; Roussou M; Kanellias N; Ziogas D; Dialoupi I; Eleutherakis Papaiakovou E; Kastritis E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):23-28. PubMed ID: 30224328
[TBL] [Abstract][Full Text] [Related]
31. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
32. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
33. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
[TBL] [Abstract][Full Text] [Related]
34. Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia.
Tripsas CK; Patterson CJ; Uljon SN; Lindeman NI; Turnbull B; Treon SP
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):250-2. PubMed ID: 23664027
[TBL] [Abstract][Full Text] [Related]
35. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.
Pasricha SR; Juneja SK; Westerman DA; Came NA
J Clin Pathol; 2011 Jun; 64(6):520-3. PubMed ID: 21471142
[TBL] [Abstract][Full Text] [Related]
36. Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
Montoto S; Rozman M; Rosiñol L; Nadal E; Giné E; Aymerich M; Ferrer A; Esteve J; Bosch F; López-Guillermo A; Bladé J; Montserrat E
Semin Oncol; 2003 Apr; 30(2):178-81. PubMed ID: 12720132
[TBL] [Abstract][Full Text] [Related]
37. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
Ghobrial IM; Fonseca R; Greipp PR; Blood E; Rue M; Vesole DH; Gertz MA;
Cancer; 2004 Dec; 101(11):2593-8. PubMed ID: 15493038
[TBL] [Abstract][Full Text] [Related]
38. [Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].
Tao Y; Wang S; Wang L; Wu M; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):993-997. PubMed ID: 35045669
[No Abstract] [Full Text] [Related]
39. Waldenström macroglobulinemia.
Gertz MA
Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
[TBL] [Abstract][Full Text] [Related]
40. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
Xu L; Hunter ZR; Tsakmaklis N; Cao Y; Yang G; Chen J; Liu X; Kanan S; Castillo JJ; Tai YT; Zehnder JL; Brown JR; Carrasco RD; Advani R; Sabile JM; Argyropoulos K; Lia Palomba M; Morra E; Trojani A; Greco A; Tedeschi A; Varettoni M; Arcaini L; Munshi NM; Anderson KC; Treon SP
Br J Haematol; 2016 Mar; 172(5):735-44. PubMed ID: 26659815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
